Innovent Biologics

05/08/2025

We're pleased to share that the U.S. FDA has approved the IND application for IBI3032, Innovent's novel oral GLP-1R agonist, enabling the start of Phase 1 trials in both the U.S. and China. With promising preclinical data and global potential, IBI3032 represents a key milestone in the continued expansion of our CVM pipeline. https://www.prnewswire.com/news-releases/innovent-receives-us-fda-approval-for-ind-application-of-oral-glp-1r-agonist-ibi3032-302520701.html?tc=eml_cleartime

01/08/2025

On World Lung Cancer Day, we recognize the urgent global and national impact of lung cancer, the leading cause of cancer death worldwide, with over 800,000 new cases diagnosed annually in China alone.

At Innovent, we are advancing a broad portfolio of therapies across multiple indications in lung cancer, including TYVYT® (sintilimab) and Byvasda® (bevacizumab), limertinib for EGFR-mutant NSCLC, Dovbleron® for ROS1-positive tumors, IBI363 for patients who have progressed after immunotherapy, and more. We stand with the community in raising awareness, encouraging early detection, and advocating for continued investment in research to bring forward a future with more hope and better care.

28/07/2025

On World Hepatitis Day, we stand with the global call to break down barriers to hepatitis and liver cancer care. At Innovent, we're committed to advancing science and expanding access to innovative therapies to help combat liver cancer and improve outcomes for patients.

22/07/2025

Nature Medicine has published the Phase 1 results of IBI343, Innovent’s anti-CLDN18.2 ADC, highlighting its potential as a treatment for advanced gastric and gastroesophageal junction adenocarcinoma. This milestone publication reflects growing global recognition of China’s progress in cancer innovation and supports further studies to bring new treatment options to patients with advanced G/GEJ AC.

Read more about our global, multi-center Phase 1 trial here: https://www.nature.com/articles/s41591-025-03783-8

https://en.prnasia.com/releases/global/nature-medicine-published-phase-1-results-of-innovent-biologics-anti-cldn18-2-adc-ibi343-in-patients-with-advanced-gastric-gastroesophageal-junction-adenocarcinoma-496827.shtml

01/07/2025

FirstWord Pharma featured Innovent Biologics’ latest milestone as a top story: the approval of mazdutide in China for chronic weight management. As the article highlights, this first-in-class dual GCG/GLP-1 receptor agonist, backed by strong Phase 3 data, opens an exciting new chapter in obesity treatment. Read more within!https://firstwordpharma.com/story/5976911

01/07/2025

Innovent recently hosted its Oncology R&D Day, unveiling a bold global strategy powered by dual innovation in next-generation immuno-oncology and ADC technologies. With over 500 global stakeholders in attendance, the event highlighted our dedication to redefining cancer care through cutting-edge science and a robust, globally competitive pipeline. As we accelerate toward global MRCT Phase 3 trials by 2030, we remain focused on delivering innovative, accessible treatments to patients worldwide. Learn more about R&D Day and our strategy here: https://en.prnasia.com/releases/global/innovent-biologics-showcases-dual-innovations-at-oncology-r-d-day-pioneering-the-future-of-cancer-treatment-with-next-generation-io-and-adc-platforms-494875.shtml

27/06/2025

China's NMPA has approved mazdutide, the world's first dual GCG/GLP-1 receptor agonist, for chronic weight management in adults with overweight or obesity.

Mazdutide offers a novel mechanism that boosts weight-loss efficacy, reduces visceral fat, and delivers broad metabolic benefits. It was named one of Fierce Pharma's Top 10 Most Anticipated Drugs of 2025.

This approval aligns with China's new “Healthy Weight Management Action” under the Healthy China 2030 initiative, marking a timely step in addressing the country's growing obesity challenge. It marks Innovent's 16th approved drug in 14 years and reflects our commitment to accelerating access to innovative therapies in CVM health and beyond.
https://en.prnasia.com/releases/global/innovent-announces-mazdutide-first-dual-gcg-glp-1-receptor-agonist-received-approval-from-china-s-nmpa-for-chronic-weight-management-494728.shtml

25/06/2025

We're proud to share that Phase 3 results from the DREAMS-1 study of mazdutide, a dual GCG/GLP-1 receptor agonist, were presented at the 85th ADA Scientific Sessions, demonstrating significant improvements in glycemic control, weight loss, and cardiometabolic health in Chinese adults with type 2 diabetes. With the NDA now under review by China's NMPA, mazdutide has the potential to become a next-generation treatment option for T2D in China.



https://en.prnasia.com/releases/global/innovent-announces-the-phase-3-clinical-study-dreams-1-of-mazdutide-in-china-were-orally-presented-at-ada-85th-scientific-sessions-494239.shtml

25/06/2025

Join us for Innovent Biologics' Oncology R&D Day on June 28 in Shanghai, with live webcast access available globally.

Our leadership team will present updates on our oncology pipeline, alongside expert insights into global trends and scientific progress in cancer treatment.

Date: June 28, 2025
Time: 8:30 AM – 12:20 PM (China Standard Time)
Language: Mandarin (English simultaneous translation available)

Register below!

23/06/2025

Hello Chicago!

Excited to share that multiple exploratory MoA analyses of mazdutide and a preclinical study of IBI3030 (PCSK9-GGG) will be featured at . These presentations reflect our strategic focus on advancing innovative therapies and expanding our growing pipeline in cardiovascular and metabolic diseases. Details on where to find us here: https://en.prnasia.com/releases/global/multiple-research-results-from-innovent-s-general-biomedicine-pipeline-to-be-showcased-at-the-ada-85th-scientific-sessions-493915.shtml

19/06/2025

Citeline has just featured our expanding innovation footprint across key therapeutic areas.

At , Innovent presented data from four trials of IBI363, a first-in-class PD-1/IL-2α-bias bispecific antibody, with encouraging overall survival outcomes in NSCLC, melanoma, and colorectal cancer, all pointing to IBI363's potential as a next-generation immunotherapy.

The article also spotlights our expanding metabolic pipeline, including mazdutide, nearing first approvals in China for T2D and obesity, and IBI3030, a novel PCSK9-targeting antibody-peptide conjugate.

As CEO Dr. Michael Yu shared with Citeline, the variety and quality of drug development emerging from China are becoming globally competitive, and Innovent is proud to be at the forefront.

Check out the full article: https://insights.citeline.com/scrip/focus-on-asia/china/innovent-builds-metabolic-pipeline-while-retaining-oncology-backbone-6HKTI7IZO5DPNFGY5444OWQ7XI/

Innovent presented data on multiple pipeline assets at ASCO, including promising OS results for its first-in-class anti-PD-1/IL-2α-bias bispecific. The Chinese firm is also continuing to build out its metabolic disease portfolio and consider its partnering strategies, its CEO tells Scrip.

17/06/2025

Samuel Zhang, Global Chief Business Officer at Innovent, recently spoke with Bloomberg on The China Show about the growing momentum in China's biotech sector.

In the interview, Dr. Zhang shares how Innovent is positioned to lead in what Bloomberg calls biotech's “DeepSeek moment” driven by our expanding pipeline and long-term strategy for sustainable growth.

Watch the full segment here:https://www.bloomberg.com/news/videos/2025-06-16/innovent-on-seizing-deepseek-moment-for-biotech-video